Related Experiment Video
Updated: Jul 4, 2025
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
Metabolomics in liver diseases: A novel alternative for liver biopsy?
1Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo 162-8655, Japan. ytanaka@hosp.ncgm.go.jp.
Insights
Hepatitis C virus (HCV) infection causes liver fibrosis, a key factor in patient prognosis. Metabolomics offers a promising noninvasive approach to assess fibrosis staging, potentially replacing traditional liver biopsies.
Area of Science:
- Hepatology
- Virology
- Metabolomics
Background:
- Chronic Hepatitis C virus (HCV) infection is a leading cause of liver fibrosis, significantly impacting patient outcomes.
- Traditional liver biopsy for fibrosis evaluation is invasive, costly, and prone to sampling errors and interpretation variability.
- Noninvasive methods like fibrotic markers, blood test scoring systems, and imaging techniques have been developed to assess liver fibrosis.
Discussion:
- Metabolomics, an emerging technology, shows potential for diagnosing and staging liver fibrosis in chronic HCV infection.
- This editorial comments on recent research utilizing metabolome analysis to decode fibrosis grading and underlying pathways in HCV.
- The discussion highlights previous studies on metabolome analysis for diagnosing HCV-related liver fibrosis.
Key Insights:
- Metabolomics analysis can accurately detect and stage liver fibrosis in patients with chronic Hepatitis C virus infection.
- Metabolomic profiling provides insights into the biological pathways underlying liver fibrosis development.
- Noninvasive metabolomics-based diagnostics could complement or replace traditional liver biopsy methods.
Outlook:
- Further research into metabolomics can lead to the development of novel, noninvasive, biopsy-free diagnostic techniques for liver fibrosis.
- Metabolomics may offer a more accessible and cost-effective method for monitoring fibrosis progression and treatment response in HCV patients.
- Integration of metabolomics into clinical practice could improve the management and prognosis of chronic Hepatitis C.
Abstract:
Hepatitis C virus (HCV) remains a significant public health problem as it can cause acute and chronic hepatitis. Chronic HCV infection is a major cause of liver fibrosis, and evaluation of liver fibrosis is essential because the prognosis of patients with chronic HCV infection is closely related to the stage of fibrosis. Liver fibrosis is traditionally evaluated based on pathological analysis of biopsy specimens, which is considered the gold standard. Nevertheless, liver biopsy is invasive and susceptible to sampling error and inter- and intraobserver variation in pathological interpretation; it is also costly. Therefore, noninvasive diagnostic investigations have been developed, including the use of fibrotic markers, scoring systems based on routine blood tests, and transient elastography with magnetic resonance imaging or ultrasonography. Recently, metabolomics, an emerging technology, has been used to detect the fibrosis stage. In this editorial, I comment on the article titled "Metabolomics in chronic hepatitis C: Decoding fibrosis grading and underlying pathways" by Ferrasi et al published in the recent issue of the World Journal of Hepatology. I discuss previous studies on the use of metabolome analysis for the diagnosis of HCV-related liver fibrosis and the potential development of biopsy-free diagnostic techniques.
More Related Videos
07:54Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy
Published on: December 15, 2011
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
